Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Masafumi Nakamura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5584-8311; OpenAlex author ID A5101779405. Sources: OpenAlex.

Their work

Papers
24 (first author 1, last author 19)
Trials
0
Grants
0
Labs led
1
Collaborators
75
Papers, trials and grants by year

2016: 1 paper · 2017: 3 papers · 2018: 2 papers · 2019: 4 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 5 papers · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 24

  1. Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled… Co-author DOI 10.1097/sla.0000000000006900↗
  2. Efficacy and Safety of Surgical Treatment Among Older Adult Patients (80 Years) With Pancreatic Cancer: A Systematic Review and Meta-Analysis. Last author DOI 10.1002/jhbp.12151↗
  3. Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.surg.2024.108958↗
  4. Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study. Co-author DOI 10.3389/fimmu.2025.1571182↗
  5. MicroRNA-20a in extracellular vesicles derived from duodenal fluid is a possible biomarker for pancreatic ductal adenocarcinoma. Last author DOI 10.1002/deo2.333↗
  6. A Novel Oncolytic Viral Therapy Using Coxsackievirus B3 (CVB3) for Human Pancreatic Cancer Including Cancer-associated Fibroblasts. Co-author DOI 10.21873/anticanres.17348↗
  7. Extracellular volume fraction determined by dual-layer spectral detector CT: Possible role in predicting the efficacy of preoperative neoadjuvant chemotherapy … Co-author DOI 10.1016/j.ejrad.2023.110756↗
  8. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arte… Last author DOI 10.1245/s10434-022-12566-1↗
  9. ASO Author Reflections: Novel Evidence on Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer with Arterial Involvement. Last author DOI 10.1245/s10434-022-12584-z↗
  10. Prognostic Impact of Preoperative Osteosarcopenia for Patients with Pancreatic Ductal Adenocarcinoma After Curative Resection. Last author DOI 10.1245/s10434-023-13936-z↗
  11. C4orf47 contributes to the dormancy of pancreatic cancer under hypoxic conditions. Last author DOI 10.7150/jca.78993↗
  12. Extensive (subtotal) distal pancreatectomy for pancreatic ductal adenocarcinoma: a propensity score matched cohort study of short- and long-term outcomes compa… Last author DOI 10.1007/s00423-022-02453-4↗
  13. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Mult… Last author DOI 10.29337/ijsp.142↗
  14. Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy. Last author DOI 10.1097/cji.0000000000000305↗
  15. CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis. Last author DOI 10.1007/s00432-019-02860-z↗
  16. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-019-07269-z↗
  17. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery. Last author DOI 10.1245/s10434-019-07309-8↗
  18. ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcome… First author DOI 10.1245/s10434-019-07857-z↗
  19. Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2018.03.031↗
  20. Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-018-6761-6↗
  21. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer. Last author DOI 10.1016/j.surg.2016.10.035↗
  22. Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated With Pancreatic Cancer Progression and Promotes Growth of Pancreatic Tumors in Mi… Last author DOI 10.1053/j.gastro.2017.01.010↗
  23. Cancer-associated peritoneal mesothelial cells lead the formation of pancreatic cancer peritoneal dissemination. Last author DOI 10.3892/ijo.2016.3829↗
  24. Comparison of Surgical Outcomes Between Radical Antegrade Modular Pancreatosplenectomy (RAMPS) and Standard Retrograde Pancreatosplenectomy (SPRS) for Left-Sid… Last author DOI 10.1007/s00268-016-3526-x↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kohei Nakata · 15 shared papers, 2017–2025 · strength 1.83
  2. Takao Ohtsuka · 15 shared papers, 2016–2025 · strength 1.82
  3. Naoki Ikenaga · 8 shared papers, 2022–2025 · strength 1.67
  4. Yoshihiro Miyasaka · 13 shared papers, 2016–2023 · strength 1.37
  5. Toshiya Abe · 10 shared papers, 2016–2025 · strength 1.17
  6. Yoshinao Oda · 10 shared papers, 2016–2024 · strength 1.00
  7. Noboru Ideno · 4 shared papers, 2022–2025 · strength 0.76
  8. Kenoki Ohuchida · 9 shared papers, 2016–2024 · strength 0.74
  9. Hideya Onishi · 5 shared papers, 2019–2025 · strength 0.73
  10. Kousei Ishigami · 4 shared papers, 2023–2025 · strength 0.72
  11. Nao Fujimori · 4 shared papers, 2019–2025 · strength 0.67
  12. Nobuhiro Fujita · 3 shared papers, 2023–2025 · strength 0.57
  13. Masayuki Sho · 2 shared papers, 2025–2026 · strength 0.53
  14. Yasuhisa Mori · 5 shared papers, 2017–2022 · strength 0.49
  15. Akira Imaizumi · 3 shared papers, 2020–2024 · strength 0.45
  16. Kazuyoshi Nishihara · 3 shared papers, 2021–2023 · strength 0.45
  17. So Nakamura · 3 shared papers, 2019–2024 · strength 0.44
  18. Yusuke Watanabe · 2 shared papers, 2022–2025 · strength 0.40
  19. Chika Iwamoto · 4 shared papers, 2017–2025 · strength 0.39
  20. Takashi Morisaki · 2 shared papers, 2020–2025 · strength 0.30
  21. Hiroaki Nagano · 2 shared papers, 2021–2023 · strength 0.27
  22. Susumu Eguchi · 2 shared papers, 2021–2023 · strength 0.27
  23. Masafumi Inomata · 2 shared papers, 2021–2023 · strength 0.27
  24. Hirokazu Noshirο · 2 shared papers, 2021–2023 · strength 0.27
  25. Makoto Kawamoto · 2 shared papers, 2020–2023 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.